Skip to main content
. 2016 Dec 19;28(3):642–650. doi: 10.1093/annonc/mdw670

Figure 3.

Figure 3.

(A) KRASG12/G13 mutant allele frequencies (MAFs) at baseline (median, 0.50%), during therapy (median, 0.22%), and at disease progression (median, 1.13%) differed significantly (P =0.04). (B) KRASG12/G13 copy numbers at baseline (median, 14), during therapy (median, 17), and at disease progression (median, 273) differed significantly (P =0.03).